BRPI0511897A - método para tratar distúrbios de glándula sebácea hiperativa, e, uso de uma composição fotossensibilizadora hidrofóbica e/ou lipofìlica - Google Patents

método para tratar distúrbios de glándula sebácea hiperativa, e, uso de uma composição fotossensibilizadora hidrofóbica e/ou lipofìlica

Info

Publication number
BRPI0511897A
BRPI0511897A BRPI0511897-2A BRPI0511897A BRPI0511897A BR PI0511897 A BRPI0511897 A BR PI0511897A BR PI0511897 A BRPI0511897 A BR PI0511897A BR PI0511897 A BRPI0511897 A BR PI0511897A
Authority
BR
Brazil
Prior art keywords
hydrophobic
lipophilic
gland disorders
sebaceous gland
photosensitizing composition
Prior art date
Application number
BRPI0511897-2A
Other languages
English (en)
Inventor
Alain H Curaudeau
Herma Neyndorff
Jing-Song Tao
Julia G Levy
David W C Hunt
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002470403A external-priority patent/CA2470403A1/en
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of BRPI0511897A publication Critical patent/BRPI0511897A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODO PARA TRATAR DISTúRBIOS DE GLáNDULA SEBáCEA HIPERATIVA, E, USO DE UMA COMPOSIçãO FOTOSSENSIBILIZADORA HIDROFóBICA E/OU LIPOFìLICA O presente método envolve o tratamento fotodinâmico de distúrbios de glândula hiperativa. O método envolve a administração tópica de uma composição fotossensibilizadora compreendendo porfirinas verdes hidrofóbicas e/ou lipofilicas tais como lemuteporfina, polietileno glicol e realçadores da penetração dérmica tais como álcool oleílico e TRANSCUTOL<32> para afetar a pele e a exposição subseqüente desta pele à energia de um comprimento de onda capaz de ativar o fotossensibilizador.
BRPI0511897-2A 2004-06-09 2005-02-08 método para tratar distúrbios de glándula sebácea hiperativa, e, uso de uma composição fotossensibilizadora hidrofóbica e/ou lipofìlica BRPI0511897A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002470403A CA2470403A1 (en) 2004-02-06 2004-06-09 Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders
PCT/CA2005/000154 WO2005120572A1 (en) 2004-06-09 2005-02-08 Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins

Publications (1)

Publication Number Publication Date
BRPI0511897A true BRPI0511897A (pt) 2008-01-15

Family

ID=37649609

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511897-2A BRPI0511897A (pt) 2004-06-09 2005-02-08 método para tratar distúrbios de glándula sebácea hiperativa, e, uso de uma composição fotossensibilizadora hidrofóbica e/ou lipofìlica

Country Status (11)

Country Link
EP (1) EP1755676B1 (pt)
JP (1) JP2008501727A (pt)
AU (1) AU2005251395A1 (pt)
BR (1) BRPI0511897A (pt)
CA (1) CA2568744A1 (pt)
DK (1) DK1755676T3 (pt)
ES (1) ES2400566T3 (pt)
MX (1) MX2007000338A (pt)
NZ (1) NZ551636A (pt)
WO (1) WO2005120572A1 (pt)
ZA (1) ZA200610239B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2724949A1 (en) 2007-06-27 2008-12-31 The General Hospital Corporation Method and apparatus for optical inhibition of photodynamic therapy
EP2231105A1 (en) * 2007-12-14 2010-09-29 Photoderma SA Novel compounds useful in therapeutic and cosmetic methods
WO2009093144A2 (en) * 2008-01-25 2009-07-30 Qlt, Inc.Lau Photodynamic therapy of sebaceous gland disorders
FR2927800A1 (fr) * 2008-02-25 2009-08-28 Oreal Association d'un rayonnement lumineux et d'un compose bioconvertible par la lipase pour ameliorer l'apparence de la peau et/ou du cheveu.
WO2010071230A1 (ja) 2008-12-17 2010-06-24 学校法人慶應義塾 細胞特異的能動集積性を有する光線力学療法剤
EP2663285A2 (en) * 2011-01-13 2013-11-20 Qlt Inc. Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
WO2013092505A1 (en) * 2011-12-19 2013-06-27 Photocure Asa Irradiation apparatus
HU230989B1 (hu) * 2013-01-17 2019-08-28 Gd Photonics Kft. Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak előállítására és alkalmazása
EP3799868A1 (en) * 2013-12-20 2021-04-07 Galderma Research & Development Pulse photodynamic treatment of photodamaged skin
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
US11331304B2 (en) 2016-05-11 2022-05-17 The Jackson Laboratory YAP1 inhibitors and methods
FR3109086A1 (fr) 2020-04-14 2021-10-15 Ifremer utilisation d’un extrait polaire de Skeletonema dans une thérapie photodynamique

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
US5955490A (en) 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US6492420B2 (en) * 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
IL116126A0 (en) 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
US6004821A (en) 1998-03-07 1999-12-21 Levine; Robert A. Method and apparatus for performing chemical, qualitative, quantitative, and semi-quantitative analyses of a urine sample
JP2002526128A (ja) 1998-07-09 2002-08-20 キュアライト・リミテッド にきび及び脂漏症のために有効な高エネルギ光力学治療装置及び方法
US6887260B1 (en) * 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US6183773B1 (en) * 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
GB0005855D0 (en) 2000-03-10 2000-05-03 Scotia Holdings Plc Compounds for pdt
GB2360459B (en) 2000-03-23 2002-08-07 Photo Therapeutics Ltd Therapeutic light source and method
GB2361430A (en) 2000-04-17 2001-10-24 Photo Therapeutics Ltd Therapeutic discharge lamps
ATE463237T1 (de) 2000-08-16 2010-04-15 Gen Hospital Corp Topische aminolevulinsäure-photodynamische therapie für akne vulgaris
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7018396B2 (en) * 2001-08-07 2006-03-28 New England Medical Center Hospitals, Inc. Method of treating acne
US20050090481A1 (en) * 2001-11-09 2005-04-28 Qlt Inc Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment
US20040073277A1 (en) * 2002-04-05 2004-04-15 Geronemus Roy G. High fluence rate activation of photosensitizers for dermatological applications
CA2457214A1 (en) * 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne

Also Published As

Publication number Publication date
ES2400566T3 (es) 2013-04-10
EP1755676A1 (en) 2007-02-28
AU2005251395A1 (en) 2005-12-22
WO2005120572A1 (en) 2005-12-22
ZA200610239B (en) 2008-06-25
EP1755676A4 (en) 2010-12-22
NZ551636A (en) 2009-12-24
JP2008501727A (ja) 2008-01-24
CA2568744A1 (en) 2005-12-22
MX2007000338A (es) 2007-03-28
DK1755676T3 (da) 2013-02-18
EP1755676B1 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
BRPI0511897A (pt) método para tratar distúrbios de glándula sebácea hiperativa, e, uso de uma composição fotossensibilizadora hidrofóbica e/ou lipofìlica
BRPI0507406A (pt) método de tratamento de acne vulgaris, e, uso de um fotossensibilizante de porfirina verde e solubilizador
Darlenski et al. Photodynamic therapy in dermatology: past, present, and future
Forster et al. Penetration enhancement of two topical 5‐aminolaevulinic acid formulations for photodynamic therapy by erbium: YAG laser ablation of the stratum corneum: continuous versus fractional ablation
Lee et al. Fractional laser as a tool to enhance the skin permeation of 5-aminolevulinic acid with minimal skin disruption: a comparison with conventional erbium: YAG laser
Lopez et al. Enhanced Delivery of 5‐Aminolevulinic Acid Esters by Iontophoresis In Vitro¶
Gerritsen et al. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy
Haedersdal et al. Enhanced uptake and photoactivation of topical methyl aminolevulinate after fractional CO2 laser pretreatment
Genina et al. Low-intensity indocyanine-green laser phototherapy of acne vulgaris: pilot study
Fink-Puches et al. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light
Ross Optical treatments for acne
Issa et al. Topical delivery of triamcinolone via skin pretreated with ablative radiofrequency: a new method in hypertrophic scar treatment
Angelo et al. Chemical and physical strategies in onychomycosis topical treatment: A review
JP6933685B2 (ja) 光損傷皮膚のパルス光力学的処置
FR2924021B1 (fr) Composition pour le traitement de la peau par therapie photodynamique
BR0213996A (pt) Método e aparelho para estimular o crescimento capilar
Cho et al. Therapeutic efficacy and safety of a 1927-nm fractionated thulium laser on pattern hair loss: an evaluator-blinded, split-scalp study
WO2000040266A3 (en) Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
Gupta et al. Medical devices for the treatment of onychomycosis
WO2000028971A1 (de) 5-aminolävulinsäure-nanoemulsion
Samy et al. Effect of methylene blue-mediated photodynamic therapy for treatment of basal cell carcinoma
Rhee et al. Effect of low-level laser treatment on cochlea hair-cell recovery after acute acoustic trauma
JP2024050723A (ja) 皮膚障害に対する光線力学的治療方法
Shan et al. An open uncontrolled trial of topical 5-aminolevulinic acid photodynamic therapy for the treatment of urethral condylomata acuminata in male patients
US20080146667A1 (en) Method of treatment of skin

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.